



Public Health and Clinical Malaria in the U.S.

Seymour Williams, MD, MPH

Malaria Branch

Division of Parasitic Diseases and Malaria

BLOOD PRODUCTS ADVISORY COMMITTEE meeting

May 9, 2024

Public Health and Clinical Malaria in the U.S.: Outline

- Brief on Biology/Burden/History
- Surveillance & Epidemiology
- Prevention and Clinical Care
- Local malaria outbreak, U.S., 2023

Malaria: a parasitic disease transmitted by *Anopheles* mosquitos

- 5 species of *Plasmodium* cause human disease
 - *P. falciparum*
 - *P. vivax* (relapsing)
 - *P. ovale* (relapsing)
 - *P. malariae*
 - *P. knowlesi* (zoonotic)




Figure 1: Life cycle of the malaria parasite

Adapted from Good MF. Vaccine-induced immunity to malaria parasites and the need for novel strategies. *Trends Parasitol* 2005; **21**: 29–34.

Mechanisms of Malaria Transmission, US



- **Mosquito**



- **Congenital**



- **Blood transfusions**



- **Organ transplant**



- **Sharing needles or syringes**

Credits

Blood in bag : <https://pixels.com/featured/blood-transfusion-antonia-reeves-science-photo-library.html>

Organ box- <https://www.news-medical.net/health/How-has-COVID-19-affected-Organ-Transplantation.aspx>


Sharing needles-

<https://www.northridgeaddiction.com/recovery-blog/intravenous-drug-use/dangers-of-drug-injection-use-and-sharing-needles/>

Baby in utero: Magic nine/Shutterstock.com in

<https://www.news-medical.net/health/What-is-Vertical-Transmission.aspx>

Global Malaria cases, 2023



Over 99% of malaria cases in U.S., among individuals reporting travel to or from malaria-endemic region ≤1 year of presentation


MALARIA IN THE UNITED STATES

SEVERE SERIOUS LESS SERIOUS SPORADIC

QUININE... Prescribed in grains, produced in tons.

CINCHONA... Quinine comes from the bark of a Cinchona tree, a native of South America, but best grown in Java.

MALARIA... Quinine is a world-wide remedy for malaria. For the correct dosage see your doctor or health officer.



Malaria in the United States, early 1940s

~65,000 cases/yr

Source: NLM/NIH
Cinchona Inc. NYC

Malaria Surveillance


Malaria case investigation




LOCAL RECORD ID: _____		LOCAL SUBJECT ID: _____	
1. DEMOGRAPHIC AND CARE PROVIDER INFORMATION:			
a. Subject name (Last, First) _____ Date of symptom onset of this illness: * _____		e. Age: _____ Age units: yrs mos. wks. days Date of Birth (mm/dd/yyyy): _____	h. Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Unknown
b. State/territory reporting this case: _____ Subject's county of residence: _____		f. Height: _____ Height units: centimeters inches	i. Pregnant?: <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown
c. Physician name: (include additional physicians on the continuation page) First and Last Name _____ Phone _____		g. Weight: _____ Weight units: kg g lb oz	
d. Hospitalization: (include additional hospitalizations on the continuation page) Subject admitted as inpatient: <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown. Admission date (mm/dd/yyyy) _____ Discharge date (mm/dd/yyyy) _____ Hospital name: _____ Hospital record No.: _____ Hospital duration (in days): _____		j. Ethnicity: <input type="checkbox"/> Hispanic or Latino <input type="checkbox"/> Not Hispanic or Latino <input type="checkbox"/> Unknown	k. Race (select one or more): <input type="checkbox"/> American Indian/Alaska Native <input type="checkbox"/> Native Hawaiian/Other Pacific Islander <input type="checkbox"/> Black or African American <input type="checkbox"/> Asian <input type="checkbox"/> White <input type="checkbox"/> Unknown <input type="checkbox"/> Other, Specify _____
2. LABORATORY RESULTS: Complete a minimum of one positive malaria diagnostic test. If more than two tests were done then additional results may be included on the continuation page. It is preferable to include the following tests: (i) blood smear with the highest percentage parasitemia, (ii) the test that indicates the Plasmodium species, and (iii) a confirmatory PCR (if applicable). For conflicting lab results for the species identification, include only the test with the final result. For a lab result that identifies more than one species, multiple species can be selected for that one test. If the species determination is inconclusive, then select "Not determined"; if there is a suspicion towards a particular species (e.g. "non-falciparum" select "Not determined" and "Other" and write the suspected species in the "Other species, specify" section.			
I. Diagnostic lab test. a. Type: <input type="checkbox"/> Blood Smear <input type="checkbox"/> PCR <input type="checkbox"/> RDT <input type="checkbox"/> Other <input type="checkbox"/> No test done/unknown Specimen collection date (mm/dd/yyyy): _____ Lab result date (mm/dd/yyyy): _____		II. Diagnostic lab test. a. Type: <input type="checkbox"/> Blood Smear <input type="checkbox"/> PCR <input type="checkbox"/> RDT <input type="checkbox"/> Other <input type="checkbox"/> No test done/unknown Specimen collection date (mm/dd/yyyy): _____ Lab result date (mm/dd/yyyy): _____	
b. Result: <input type="checkbox"/> Pos <input type="checkbox"/> Neg <input type="checkbox"/> Unknown <input type="checkbox"/> Not done c. Species: <input type="checkbox"/> Vivax <input type="checkbox"/> Falciparum <input type="checkbox"/> Malariae <input type="checkbox"/> Ovale <input type="checkbox"/> Not Determined <input type="checkbox"/> Other species (specify): _____		b. Result: <input type="checkbox"/> Pos <input type="checkbox"/> Neg <input type="checkbox"/> Unknown <input type="checkbox"/> Not done c. Species: <input type="checkbox"/> Vivax <input type="checkbox"/> Falciparum <input type="checkbox"/> Malariae <input type="checkbox"/> Ovale <input type="checkbox"/> Not Determined <input type="checkbox"/> Other species (specify): _____	
d. Parasitemia (%): _____ Lab name: _____ Lab phone: _____		d. Parasitemia (%): _____ Lab name: _____ Lab phone: _____	
3. TRAVEL HISTORY: If more than four countries were visited in the past two years then add responses on the continuation page. Additional travel details (e.g. city or region of travel, acclimation of dates or duration, etc.) can be provided in the comments section.			
a. Has the subject traveled or lived outside the U.S. during the past 2 years? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
b. If yes, specify Country: _____ (If unable to determine country, select appropriate region (e.g. South America). Date returned/ arrived in US: _____			
Duration in country: _____ Duration units: yrs. mos. wks. days			
c. Principal reason for travel: _____ Other reason for travel: _____			
d. What is the subject's country of usual residence? _____		e. What is the subject's country of residence prior to most recent travel? _____	f. What is the subject's country of birth? _____
4. SPECIMEN: Was a specimen(s) sent to CDC? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown If yes, type of specimen sent to CDC (For each specimen, enter the CDC ID)		b. Specimen Type 1. _____ 2. _____ 3. _____ 4. _____ 5. _____	Other specimen(s) (specify) _____ CDC ID (from 50.34 submission) _____

- Laboratory tests
- Travel history: dates, reason for travel
- Clinical: Illness onset, hospitalization, complications, chemoprophylaxis, treatments, outcome
- History: prior malaria, transfusion


Malaria surveillance in the U.S.



The number of malaria cases in the U.S. has been increasing.



Most years, every state reports at least 1 person diagnosed with malaria




SOURCE: [Malaria Surveillance— United States, 2018 | MMWR \(cdc.gov\)](#)

A preview of the 2019 – 2020 surveillance data

More than 2050 cases

2019




2020

Approx 600 cases

Global Region of Malaria acquisition, 2019 – 2020


2019: N > 2050

2020: N < 650



2019– 2020 National Malaria Surveillance data are unpublished and preliminary


US Malaria cases 2019 – 2020, onset month & species



Time interval between date of arrival in the U.S. and date of illness onset, by *Plasmodium* species, 2018

% of Plasmodium falciparum cases

% of Plasmodium vivax cases




Defining Severity of malaria cases in the US

Surveillance criteria


- Neurologic symptoms
- Acute kidney injury
- Severe anemia
- Acute respiratory distress syndrome
- 5% or higher parasitemia
- Documented IV antimalarial
- Fatal cases with malaria as cause of death

Severity of malaria cases in the US, 2019 – 2020

Uncomplicated vs. Severe




Fatality Rate



Malaria Prevention

CDC Malaria Chemoprophylaxis Recommendations

- Reviewed every two years; may be updated more frequently
- Information sources
 - WHO “Country List,” World Malaria Report, and other reports
 - Country ministries of health and malaria control programs
 - CDC Country Offices (in 62 countries)
 - U.S. President’s Malaria Initiative (in 30 countries)
 - U.S. domestic surveillance
 - Literature review
- Low-risk, conservative prevention approach for chemoprophylaxis



<https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria#prevent>



Actions for Travelers to Prevent Malaria

- Medication Prophylaxis for travel to endemic area
 - Prescribed medication based on parasite drug sensitivities
 - Take before, during and after travel
- Mosquito Avoidance
 - Insect repellants – topical and impregnated
 - Bed nets
 - Avoid being outdoors when mosquito active

Malaria Diagnosis & Treatment

Malaria Diagnostic Test Results Should be Available STAT!

- **Thick and thin blood smears (gold standard)**
 - Thick smears: most sensitive for presence of parasites
 - Thin smears: species and parasite density
- **Rapid Diagnostic Test (RDT)**
 - Can decrease time to treatment
 - Smear still required to confirm RDT result



Other Tests Not Recommended for Initial Diagnosis

- **PCR**
 - Used to identify or confirm species
 - Lengthy turnaround time
- **Serology**
 - Cannot distinguish between acute and prior infection
 - Lengthy turnaround time

Key Considerations for Malaria Treatment in the U.S.

- Management in the United States differs from endemic areas due to low malaria immunity status and available drug regimens
- Hospitalization decision
- Treatment regimen is dictated by:
 - Severity
 - Species and resistance patterns
 - Drug availability
 - Age and pregnancy status

Drugs Available in the U.S. to Treat Acute Infection of Uncomplicated Malaria

<i>P. falciparum</i> / Species unidentified (appropriate for all species)	<i>P. vivax, P. ovale, P. malariae</i>
Treatment of acute infection	Treatment of acute infection (chloroquine-susceptible)
Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) Quinine PLUS [doxycycline, clindamycin, or tetracycline] Mefloquine	Chloroquine (Aralen®) Hydroxychloroquine (Plaquenil®)

Drugs Available to Treat Severe Malaria in the U.S.

P. falciparum, *P. vivax*, *P. ovale*, *P. malariae*, species unidentified
(appropriate for all species)

IV artesunate (severe disease)

2023 Locally Acquired Malaria Cases

Anopheles mosquitoes are widespread in the US





Photo credits:

1. CDC
2. U of Fla
3. BugGuide


History of Locally Acquired Malaria in U.S., 1980-2023

- Between 1980 – 2003, 30 outbreaks of malaria occurred in 8 states

Affected states, 1980–2003
(n=8)



<https://www.cdc.gov/ncezid/dvbd/framework.html>



US Locally Acquired Malaria Cases – Florida, Texas, Maryland, Arkansas, 2023 (n=10)

<u>Species</u>	<u>State</u>	<u>County</u>	<u>Cases</u>	<u>Reported</u>
----------------	--------------	---------------	--------------	-----------------

P. vivax

Florida	Sarasota	7	May-Jul
----------------	----------	---	---------


Texas	Cameron	1	Jun
--------------	---------	---	-----

Arkansas	Saline	1	Oct
-----------------	--------	---	-----

P. falciparum

Maryland	National	1	Aug
-----------------	----------	---	-----

	Capital Region		
--	----------------	--	--



Locally Acquired Malaria 2023: Investigation Components


- **Laboratory**
 - Case confirmation & species identification
 - Genotyping
- **Epidemiological**
 - In-depth interviews to assess risk factors
 - Active case finding
 - Community engagement
- **Environmental**
 - Household visits
 - Entomologic surveillance & analysis
 - Vector control actions
- **Public Health communications**



Health Department's Malaria Investigations Revealed


- None of the local cases reported
 - Recent (< 3 years) international travel to an area with malaria
 - Blood transfusion or organ transplantation
- 3 FL cases reported experiencing homelessness

FIGURE 2. Intervals between symptom onset and health care date resulting in malaria diagnosis among patients with autochthonous malaria (N = 8) — Florida and Texas, May–July 2023




Sex and Age of Malaria cases (N = 9, *P. vivax*, US 2023)

Sex



Age (years)



Clinical Features of Malaria cases (N = 9 , *P. vivax*, US 2023)

	N (%)
Fever	9 (100)
Vomiting	6 (67)
Abdominal Pain	5 (56)
Diarrhea	3 (33)

Clinical Testing (N = 9 , *P. vivax*)

	N (%)
Thrombocytopenia	9 (100)
Anemia	7 (78)

Malaria Diagnostic Testing (N = 9 , *P. vivax*)

	N (%)
Rapid Diagnostic Test	6/6 (100)
Blood Smear (<i>P. vivax</i>)	9 (100)
PCR (<i>P. vivax</i>)	9 (100)

Treatment (N = 9 , *P. vivax*)

	N (%)
Artemether-lumefantrine	6 (67)
Atovaquone-proguanil	3 (33)
Primaquine* (antirelapse therapy)	9 (100)

*All patients had normal G6PD activity on quantitative testing

Clinical Course and Outcome

- 8/9 (89%) Hospitalized
- None developed severe malaria
- No deaths reported
- All were reported rapidly to the local/state health department or CDC Malaria Hotline

Entomological investigation and response

- *Anopheles* trapping, testing and mosquito control
- Traps placed in locations where the patients likely had mosquito exposures and where patients spent time in the evenings
- Traps and control approaches were tailored to each site



Domestic Malaria Outbreak Lessons, 2023 U.S.

- US remains at risk for sporadic mosquito outbreaks
- Essential Support/partnership with local jurisdictions
 - Surveillance
 - Laboratory
 - Entomology

Summary

The US, although endemic malaria is eliminated

- Has ~ 2000 case/yr, mainly among returning travelers visiting friends and relatives and not taking prophylaxis
- Risk of sporadic local mosquito transmission
 - Low, given small number of cases and geographically restricted
 - Competent vector
 - Delays in presentation and diagnosis
- Effective medications available to prevent and treat malaria however challenges to adherence and prompt access

Thank you

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

